Novo Nordisk on Tuesday earned FDA approval for its diabetes drug Ozempic.
Here are three things to know.
1. Ozempic is a once-weekly injection used to improve glycemic control in adults with type 2 diabetes.
2. The drug, which will cost $676 per prescription, will directly compete with Eli Lilly's diabetes drug Trulicity, according to Reuters.
3. Novo Nordisk expects Ozempic to hit the market in the first quarter of 2018.